{"transactions":[{"id":695530,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-05T20:03:45.000Z","date":"2026-08-04","kind":"sale","planned":false,"acquired":false,"shares":38800,"price":2.4589,"value":95405.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell-to-cover\" transactions and were not made at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":589355,"source":{"system":"sec-edgar","filing":"0001193125-26-335019","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526335019/ownership.xml","form_type":"4"}},{"id":695529,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26210,"kind":"person","name":"Valamehr Bahram","position":1,"cik":"0001748177","reported_name":"Valamehr Bahram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-05T20:01:39.000Z","date":"2026-08-04","kind":"sale","planned":false,"acquired":false,"shares":43947,"price":2.4598,"value":108100.8306,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell-to-cover\" transactions and were not made at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":591815,"source":{"system":"sec-edgar","filing":"0001193125-26-335007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526335007/ownership.xml","form_type":"4"}},{"id":737705,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T21:16:22.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":87900,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in full and become exercisable upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The stock option award was granted to Mr. Lee, a managing director of Redmile Group, LLC (\"Redmile\"), in connection with his service as a member of the board of directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee holds this equity award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the equity award to Redmile. Mr. Lee disclaims beneficial ownership of the equity award, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the equity award except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Lee, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile and its affiliates. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended."}],"balance_after":87900,"derivative":{"exercise_price":2.06,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":87900},"source":{"system":"sec-edgar","filing":"0001104659-26-074130","document":"tm2617974-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465926074130/tm2617974-2_4seq1.xml","form_type":"4"}},{"id":737704,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38144,"kind":"person","name":"Lee Michael Stewart","position":1,"cik":"0001748010","reported_name":"Lee Michael Stewart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T21:15:44.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":87900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in full and become exercisable upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The stock option award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC (\"Redmile\"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds this stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile. Mr. Lee disclaims beneficial ownership of the stock option award, if any, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended."}],"balance_after":87900,"derivative":{"exercise_price":2.06,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":87900},"source":{"system":"sec-edgar","filing":"0001104659-26-074126","document":"tm2617974-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465926074126/tm2617974-1_4seq1.xml","form_type":"4"}},{"id":737703,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:10:18.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":87900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":87900,"derivative":{"exercise_price":2.06,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":87900},"source":{"system":"sec-edgar","filing":"0001193125-26-271090","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526271090/ownership.xml","form_type":"4"}},{"id":737702,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38142,"kind":"person","name":"Jooss Karin","position":1,"cik":"0001754280","reported_name":"Jooss Karin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:09:36.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":87900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":87900,"derivative":{"exercise_price":2.06,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":87900},"source":{"system":"sec-edgar","filing":"0001193125-26-271088","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526271088/ownership.xml","form_type":"4"}},{"id":737701,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38107,"kind":"person","name":"EPSTEIN ROBERT S","position":1,"cik":"0001252004","reported_name":"EPSTEIN ROBERT S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:08:49.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":87900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":87900,"derivative":{"exercise_price":2.06,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":87900},"source":{"system":"sec-edgar","filing":"0001193125-26-271083","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526271083/ownership.xml","form_type":"4"}},{"id":737700,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38141,"kind":"person","name":"Agarwal Shefali","position":1,"cik":"0001746830","reported_name":"Agarwal Shefali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:08:13.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":87900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":87900,"derivative":{"exercise_price":2.06,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":87900},"source":{"system":"sec-edgar","filing":"0001193125-26-271079","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526271079/ownership.xml","form_type":"4"}},{"id":737699,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:07:22.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":87900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":87900,"derivative":{"exercise_price":2.06,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":87900},"source":{"system":"sec-edgar","filing":"0001193125-26-271074","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526271074/ownership.xml","form_type":"4"}},{"id":737698,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:06:33.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":87900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":87900,"derivative":{"exercise_price":2.06,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":87900},"source":{"system":"sec-edgar","filing":"0001193125-26-271072","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526271072/ownership.xml","form_type":"4"}},{"id":737697,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":874,"kind":"person","name":"Hamill Laura","position":1,"cik":"0001751804","reported_name":"Hamill Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:05:29.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":175800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for an equity grant upon a director's appointment or election to the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in 36 equal monthly installments following June 12, 2026, such that all of the shares shall be fully vested and exercisable on June 12, 2029, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."}],"balance_after":175800,"derivative":{"exercise_price":2.06,"expiration_date":"2036-06-12","underlying":"Common Stock","underlying_shares":175800},"source":{"system":"sec-edgar","filing":"0001193125-26-271069","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526271069/ownership.xml","form_type":"4"}},{"id":767795,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-21T20:02:44.000Z","date":"2026-05-20","kind":"sale","planned":false,"acquired":false,"shares":25590,"price":1.879,"value":48083.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 50,000 shares of Common Stock underlying performance-based RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell-to-cover\" transactions and were not made at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $1.835 to $1.935 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":628155,"source":{"system":"sec-edgar","filing":"0001193125-26-234390","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526234390/ownership.xml","form_type":"4"}},{"id":767794,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26210,"kind":"person","name":"Valamehr Bahram","position":1,"cik":"0001748177","reported_name":"Valamehr Bahram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-21T20:01:08.000Z","date":"2026-05-20","kind":"sale","planned":false,"acquired":false,"shares":28946,"price":1.8822,"value":54482.1612,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 50,000 shares of Common Stock underlying performance-based RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell-to-cover\" transactions and were not made at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $1.825 to $1.935 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":635762,"source":{"system":"sec-edgar","filing":"0001193125-26-234380","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526234380/ownership.xml","form_type":"4"}},{"id":788439,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:00:36.000Z","date":"2026-05-06","kind":"exercise","planned":false,"acquired":false,"shares":44444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":355556,"derivative":{"exercise_price":1.05,"expiration_date":"2036-01-14","underlying":"Common Stock","underlying_shares":44444},"source":{"system":"sec-edgar","filing":"0001193125-26-211820","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526211820/ownership.xml","form_type":"4"}},{"id":788438,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:00:36.000Z","date":"2026-05-06","kind":"exercise","planned":false,"acquired":false,"shares":122220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2025, such that all of the shares shall be fully vested and exercisable on January 1, 2028, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":152780,"derivative":{"exercise_price":1.32,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":122220},"source":{"system":"sec-edgar","filing":"0001193125-26-211820","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526211820/ownership.xml","form_type":"4"}},{"id":788437,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-07T20:00:36.000Z","date":"2026-05-06","kind":"exercise","planned":false,"acquired":true,"shares":44444,"price":1.05,"value":46666.2,"ownership":{"direct":true},"balance_after":653745,"source":{"system":"sec-edgar","filing":"0001193125-26-211820","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526211820/ownership.xml","form_type":"4"}},{"id":788436,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-07T20:00:36.000Z","date":"2026-05-06","kind":"exercise","planned":false,"acquired":true,"shares":122220,"price":1.32,"value":161330.4,"ownership":{"direct":true},"balance_after":609301,"source":{"system":"sec-edgar","filing":"0001193125-26-211820","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526211820/ownership.xml","form_type":"4"}},{"id":789838,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38107,"kind":"person","name":"EPSTEIN ROBERT S","position":1,"cik":"0001252004","reported_name":"EPSTEIN ROBERT S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-06T20:01:46.000Z","date":"2026-05-05","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vested and became exercisable on the date of the 2017 Annual Meeting of Stockholders."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2026-05-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-208899","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526208899/ownership.xml","form_type":"4"}},{"id":789837,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38107,"kind":"person","name":"EPSTEIN ROBERT S","position":1,"cik":"0001252004","reported_name":"EPSTEIN ROBERT S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T20:01:46.000Z","date":"2026-05-05","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":1.69,"value":42250.0,"ownership":{"direct":true},"balance_after":36331,"source":{"system":"sec-edgar","filing":"0001193125-26-208899","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526208899/ownership.xml","form_type":"4"}},{"id":789836,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-06T20:00:22.000Z","date":"2026-05-05","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vested and became exercisable on the date of the 2017 Annual Meeting of Stockholders."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2026-05-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-208891","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526208891/ownership.xml","form_type":"4"}},{"id":789835,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T20:00:22.000Z","date":"2026-05-05","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":1.69,"value":42250.0,"ownership":{"direct":true},"balance_after":36331,"source":{"system":"sec-edgar","filing":"0001193125-26-208891","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526208891/ownership.xml","form_type":"4"}},{"id":801777,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Cash-settled Swaps","published_at":"2026-04-24T01:00:13.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":true,"shares":266280,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the reference price associated with the swap agreements. On April 22, 2026, the Reporting Persons filed a Form 4 that inadvertently misstated the reference price associated with the swap agreements novated by RedCo II Master Fund, L.P. (\"RedCo II\") to its two wholly-owned subsidiaries (collectively, the \"SPVs\") in the internal reorganization reported on the prior Form 4. This amendment is being filed solely to correct this administrative error and include the correct reference price."},{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction is reported to reflect that two of the Reporting Persons (Redmile and Jeremy Green, its principal) retain an indirect beneficial ownership in the securities transacted in, as reported in the row above. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"kind","element":"transactionCoding","label":"F7","text":"In connection with the reorganization of RedCo II, the swap agreements to which RedCo II was a counterparty were novated to the SPVs on a pro-rata basis, for no consideration, with no change to any other terms of the swap agreement and no change in the economic exposure."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"In connection with the reorganization of RedCo II, the swap agreements to which RedCo II was a counterparty were novated to the SPVs on a pro-rata basis, for no consideration, with no change to any other terms of the swap agreement and no change in the economic exposure."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Certain Redmile Clients are parties to swap agreements with counterparties. Each notional share subject to each swap agreement represents the economic equivalent of one share of Common Stock. These agreements do not give the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparties thereto to acquire, hold, vote or dispose of any securities of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Reporting Persons disclaim any beneficial ownership in securities that may be referenced in such swap agreements or that may be held from time to time by any counterparties to the agreements."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Redmile Clients that are parties to the swap agreements have the right to close out each swap at any time. Upon settlement of the various swap agreements, either (i) the counterparty will pay to the Redmile Clients in cash an amount determined in part by reference to any increase between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement or (ii) the Redmile Clients will pay to the counterparty in cash an amount determined in part by reference to any decrease between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reported securities are directly owned by certain private investment vehicles managed by Redmile (collectively, the \"Redmile Clients\"), excluding RedCo II but including the SPVs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are directly owned by certain private investment vehicles managed by Redmile (collectively, the \"Redmile Clients\"), excluding RedCo II but including the SPVs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RedCo II, each of the SPVs, and each of the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":502769,"derivative":{"exercise_price":5.84,"underlying":"Common Stock","underlying_shares":266280},"source":{"system":"sec-edgar","filing":"0001104659-26-047974","document":"tm2612608-1_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465926047974/tm2612608-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2026-04-22"}},{"id":801776,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Cash-settled Swaps","published_at":"2026-04-24T01:00:13.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":false,"shares":266280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the reference price associated with the swap agreements. On April 22, 2026, the Reporting Persons filed a Form 4 that inadvertently misstated the reference price associated with the swap agreements novated by RedCo II Master Fund, L.P. (\"RedCo II\") to its two wholly-owned subsidiaries (collectively, the \"SPVs\") in the internal reorganization reported on the prior Form 4. This amendment is being filed solely to correct this administrative error and include the correct reference price."},{"field":"kind","element":"transactionCoding","label":"F7","text":"In connection with the reorganization of RedCo II, the swap agreements to which RedCo II was a counterparty were novated to the SPVs on a pro-rata basis, for no consideration, with no change to any other terms of the swap agreement and no change in the economic exposure."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"In connection with the reorganization of RedCo II, the swap agreements to which RedCo II was a counterparty were novated to the SPVs on a pro-rata basis, for no consideration, with no change to any other terms of the swap agreement and no change in the economic exposure."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Certain Redmile Clients are parties to swap agreements with counterparties. Each notional share subject to each swap agreement represents the economic equivalent of one share of Common Stock. These agreements do not give the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparties thereto to acquire, hold, vote or dispose of any securities of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Reporting Persons disclaim any beneficial ownership in securities that may be referenced in such swap agreements or that may be held from time to time by any counterparties to the agreements."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Redmile Clients that are parties to the swap agreements have the right to close out each swap at any time. Upon settlement of the various swap agreements, either (i) the counterparty will pay to the Redmile Clients in cash an amount determined in part by reference to any increase between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement or (ii) the Redmile Clients will pay to the counterparty in cash an amount determined in part by reference to any decrease between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly owned by RedCo II, a private investment vehicle managed by Redmile Group, LLC (\"Redmile\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RedCo II, each of the SPVs, and each of the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":5.84,"underlying":"Common Stock","underlying_shares":266280},"source":{"system":"sec-edgar","filing":"0001104659-26-047974","document":"tm2612608-1_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465926047974/tm2612608-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2026-04-22"}},{"id":802672,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Convertible Preferred Stock","published_at":"2026-04-23T01:51:32.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":true,"shares":162013,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F12","text":"The Class A Preferred Stock is convertible into Common Stock, in accordance with the terms of Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the \"Certificate of Designation\") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F13","text":"The one-for-five conversion rate is taken into account in the amount of underlying Common Stock involved in the transaction listed under Column 7 of Table II."},{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction is reported to reflect that two of the Reporting Persons (Redmile and Jeremy Green, its principal) retain an indirect beneficial ownership in the securities transacted in, as reported in the row above. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with an internal reorganization of RedCo II Master Fund, L.P. (\"RedCo II\"), which is one of the private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), the reported securities were distributed pro rata and in kind, for no consideration, by RedCo II to its two wholly-owned subsidiaries (collectively, the \"SPVs\"), which are also managed by Redmile. As a result, RedCo II no longer has voting or dispositive power over such securities and is no longer a beneficial owner of more than 10% of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\"), and will be dissolved. Accordingly, this Form 4 serves as an exit filing for RedCo II. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The Class A Preferred Stock is convertible into Common Stock, in accordance with the terms of Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the \"Certificate of Designation\") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The Certificate of Designation provides that the holder may not convert any shares of Class A Preferred Stock if, after giving effect to the attempted conversion, the holder and its affiliates would beneficially own in the aggregate more than 14.99% of the number of shares of Common Stock outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Class A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F14","text":"The Certificate of Designation provides that the holder may not convert any shares of Class A Preferred Stock if, after giving effect to the attempted conversion, the holder and its affiliates would beneficially own in the aggregate more than 14.99% of the number of shares of Common Stock outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Class A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F13","text":"The one-for-five conversion rate is taken into account in the amount of underlying Common Stock involved in the transaction listed under Column 7 of Table II."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reported securities are directly owned by certain private investment vehicles managed by Redmile (collectively, the \"Redmile Clients\"), excluding RedCo II but including the SPVs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are directly owned by certain private investment vehicles managed by Redmile (collectively, the \"Redmile Clients\"), excluding RedCo II but including the SPVs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RedCo II, each of the SPVs, and each of the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2755086,"derivative":{"underlying":"Common Stock","underlying_shares":810065},"source":{"system":"sec-edgar","filing":"0001104659-26-047072","document":"tm2612392-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465926047072/tm2612392-1_4seq1.xml","form_type":"4"}},{"id":802671,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Convertible Preferred Stock","published_at":"2026-04-23T01:51:32.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":false,"shares":162013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F12","text":"The Class A Preferred Stock is convertible into Common Stock, in accordance with the terms of Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the \"Certificate of Designation\") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F13","text":"The one-for-five conversion rate is taken into account in the amount of underlying Common Stock involved in the transaction listed under Column 7 of Table II."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with an internal reorganization of RedCo II Master Fund, L.P. (\"RedCo II\"), which is one of the private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), the reported securities were distributed pro rata and in kind, for no consideration, by RedCo II to its two wholly-owned subsidiaries (collectively, the \"SPVs\"), which are also managed by Redmile. As a result, RedCo II no longer has voting or dispositive power over such securities and is no longer a beneficial owner of more than 10% of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\"), and will be dissolved. Accordingly, this Form 4 serves as an exit filing for RedCo II. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with an internal reorganization of RedCo II Master Fund, L.P. (\"RedCo II\"), which is one of the private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), the reported securities were distributed pro rata and in kind, for no consideration, by RedCo II to its two wholly-owned subsidiaries (collectively, the \"SPVs\"), which are also managed by Redmile. As a result, RedCo II no longer has voting or dispositive power over such securities and is no longer a beneficial owner of more than 10% of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\"), and will be dissolved. Accordingly, this Form 4 serves as an exit filing for RedCo II. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The Class A Preferred Stock is convertible into Common Stock, in accordance with the terms of Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the \"Certificate of Designation\") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The Certificate of Designation provides that the holder may not convert any shares of Class A Preferred Stock if, after giving effect to the attempted conversion, the holder and its affiliates would beneficially own in the aggregate more than 14.99% of the number of shares of Common Stock outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Class A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F14","text":"The Certificate of Designation provides that the holder may not convert any shares of Class A Preferred Stock if, after giving effect to the attempted conversion, the holder and its affiliates would beneficially own in the aggregate more than 14.99% of the number of shares of Common Stock outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Class A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F13","text":"The one-for-five conversion rate is taken into account in the amount of underlying Common Stock involved in the transaction listed under Column 7 of Table II."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly owned by RedCo II."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RedCo II, each of the SPVs, and each of the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":810065},"source":{"system":"sec-edgar","filing":"0001104659-26-047072","document":"tm2612392-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465926047072/tm2612392-1_4seq1.xml","form_type":"4"}},{"id":802670,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Cash-settled Swaps","published_at":"2026-04-23T01:51:32.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":true,"shares":266280,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Represents the reference price associated with the swap agreements."},{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction is reported to reflect that two of the Reporting Persons (Redmile and Jeremy Green, its principal) retain an indirect beneficial ownership in the securities transacted in, as reported in the row above. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"kind","element":"transactionCoding","label":"F9","text":"In connection with the reorganization of RedCo II, the swap agreements to which RedCo II was a counterparty were novated to the SPVs on a pro-rata basis, for no consideration, with no change to any other terms of the swap agreement and no change in the economic exposure."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"In connection with the reorganization of RedCo II, the swap agreements to which RedCo II was a counterparty were novated to the SPVs on a pro-rata basis, for no consideration, with no change to any other terms of the swap agreement and no change in the economic exposure."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Certain Redmile Clients are parties to swap agreements with counterparties. Each notional share subject to each swap agreement represents the economic equivalent of one share of Common Stock. These agreements do not give the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparties thereto to acquire, hold, vote or dispose of any securities of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The Reporting Persons disclaim any beneficial ownership in securities that may be referenced in such swap agreements or that may be held from time to time by any counterparties to the agreements."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The Redmile Clients that are parties to the swap agreements have the right to close out each swap at any time. Upon settlement of the various swap agreements, either (i) the counterparty will pay to the Redmile Clients in cash an amount determined in part by reference to any increase between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement or (ii) the Redmile Clients will pay to the counterparty in cash an amount determined in part by reference to any decrease between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reported securities are directly owned by certain private investment vehicles managed by Redmile (collectively, the \"Redmile Clients\"), excluding RedCo II but including the SPVs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are directly owned by certain private investment vehicles managed by Redmile (collectively, the \"Redmile Clients\"), excluding RedCo II but including the SPVs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RedCo II, each of the SPVs, and each of the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":502769,"derivative":{"exercise_price":3.02,"underlying":"Common Stock","underlying_shares":266280},"source":{"system":"sec-edgar","filing":"0001104659-26-047072","document":"tm2612392-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465926047072/tm2612392-1_4seq1.xml","form_type":"4"}},{"id":802669,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Cash-settled Swaps","published_at":"2026-04-23T01:51:32.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":false,"shares":266280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Represents the reference price associated with the swap agreements."},{"field":"kind","element":"transactionCoding","label":"F9","text":"In connection with the reorganization of RedCo II, the swap agreements to which RedCo II was a counterparty were novated to the SPVs on a pro-rata basis, for no consideration, with no change to any other terms of the swap agreement and no change in the economic exposure."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"In connection with the reorganization of RedCo II, the swap agreements to which RedCo II was a counterparty were novated to the SPVs on a pro-rata basis, for no consideration, with no change to any other terms of the swap agreement and no change in the economic exposure."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Certain Redmile Clients are parties to swap agreements with counterparties. Each notional share subject to each swap agreement represents the economic equivalent of one share of Common Stock. These agreements do not give the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparties thereto to acquire, hold, vote or dispose of any securities of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The Reporting Persons disclaim any beneficial ownership in securities that may be referenced in such swap agreements or that may be held from time to time by any counterparties to the agreements."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The Redmile Clients that are parties to the swap agreements have the right to close out each swap at any time. Upon settlement of the various swap agreements, either (i) the counterparty will pay to the Redmile Clients in cash an amount determined in part by reference to any increase between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement or (ii) the Redmile Clients will pay to the counterparty in cash an amount determined in part by reference to any decrease between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly owned by RedCo II."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RedCo II, each of the SPVs, and each of the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.02,"underlying":"Common Stock","underlying_shares":266280},"source":{"system":"sec-edgar","filing":"0001104659-26-047072","document":"tm2612392-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465926047072/tm2612392-1_4seq1.xml","form_type":"4"}},{"id":802668,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to Purchase Common Stock","published_at":"2026-04-23T01:51:32.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":true,"shares":3691324,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction is reported to reflect that two of the Reporting Persons (Redmile and Jeremy Green, its principal) retain an indirect beneficial ownership in the securities transacted in, as reported in the row above. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with an internal reorganization of RedCo II Master Fund, L.P. (\"RedCo II\"), which is one of the private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), the reported securities were distributed pro rata and in kind, for no consideration, by RedCo II to its two wholly-owned subsidiaries (collectively, the \"SPVs\"), which are also managed by Redmile. As a result, RedCo II no longer has voting or dispositive power over such securities and is no longer a beneficial owner of more than 10% of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\"), and will be dissolved. Accordingly, this Form 4 serves as an exit filing for RedCo II. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The pre-funded warrants (\"Warrants\") are exercisable by the holder at any time until fully exercised at an exercise price per share of $0.001, subject to a limitation on the right of the Issuer to issue Common Stock if and to the extent that such exercise would cause the holder and its affiliates to beneficially own in the aggregate more than 14.99% of the combined voting power of all of the securities of the Issuer outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Warrants have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The pre-funded warrants (\"Warrants\") are exercisable by the holder at any time until fully exercised at an exercise price per share of $0.001, subject to a limitation on the right of the Issuer to issue Common Stock if and to the extent that such exercise would cause the holder and its affiliates to beneficially own in the aggregate more than 14.99% of the combined voting power of all of the securities of the Issuer outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Warrants have no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reported securities are directly owned by certain private investment vehicles managed by Redmile (collectively, the \"Redmile Clients\"), excluding RedCo II but including the SPVs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are directly owned by certain private investment vehicles managed by Redmile (collectively, the \"Redmile Clients\"), excluding RedCo II but including the SPVs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RedCo II, each of the SPVs, and each of the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3893674,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":3691324},"source":{"system":"sec-edgar","filing":"0001104659-26-047072","document":"tm2612392-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465926047072/tm2612392-1_4seq1.xml","form_type":"4"}},{"id":802667,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to Purchase Common Stock","published_at":"2026-04-23T01:51:32.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":false,"shares":3691324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with an internal reorganization of RedCo II Master Fund, L.P. (\"RedCo II\"), which is one of the private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), the reported securities were distributed pro rata and in kind, for no consideration, by RedCo II to its two wholly-owned subsidiaries (collectively, the \"SPVs\"), which are also managed by Redmile. As a result, RedCo II no longer has voting or dispositive power over such securities and is no longer a beneficial owner of more than 10% of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\"), and will be dissolved. Accordingly, this Form 4 serves as an exit filing for RedCo II. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with an internal reorganization of RedCo II Master Fund, L.P. (\"RedCo II\"), which is one of the private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), the reported securities were distributed pro rata and in kind, for no consideration, by RedCo II to its two wholly-owned subsidiaries (collectively, the \"SPVs\"), which are also managed by Redmile. As a result, RedCo II no longer has voting or dispositive power over such securities and is no longer a beneficial owner of more than 10% of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\"), and will be dissolved. Accordingly, this Form 4 serves as an exit filing for RedCo II. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The pre-funded warrants (\"Warrants\") are exercisable by the holder at any time until fully exercised at an exercise price per share of $0.001, subject to a limitation on the right of the Issuer to issue Common Stock if and to the extent that such exercise would cause the holder and its affiliates to beneficially own in the aggregate more than 14.99% of the combined voting power of all of the securities of the Issuer outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Warrants have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The pre-funded warrants (\"Warrants\") are exercisable by the holder at any time until fully exercised at an exercise price per share of $0.001, subject to a limitation on the right of the Issuer to issue Common Stock if and to the extent that such exercise would cause the holder and its affiliates to beneficially own in the aggregate more than 14.99% of the combined voting power of all of the securities of the Issuer outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Warrants have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly owned by RedCo II."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RedCo II, each of the SPVs, and each of the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":3691324},"source":{"system":"sec-edgar","filing":"0001104659-26-047072","document":"tm2612392-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465926047072/tm2612392-1_4seq1.xml","form_type":"4"}},{"id":802666,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-23T01:51:32.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":true,"shares":8977624,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction is reported to reflect that two of the Reporting Persons (Redmile and Jeremy Green, its principal) retain an indirect beneficial ownership in the securities transacted in, as reported in the row above. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with an internal reorganization of RedCo II Master Fund, L.P. (\"RedCo II\"), which is one of the private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), the reported securities were distributed pro rata and in kind, for no consideration, by RedCo II to its two wholly-owned subsidiaries (collectively, the \"SPVs\"), which are also managed by Redmile. As a result, RedCo II no longer has voting or dispositive power over such securities and is no longer a beneficial owner of more than 10% of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\"), and will be dissolved. Accordingly, this Form 4 serves as an exit filing for RedCo II. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reported securities are directly owned by certain private investment vehicles managed by Redmile (collectively, the \"Redmile Clients\"), excluding RedCo II but including the SPVs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are directly owned by certain private investment vehicles managed by Redmile (collectively, the \"Redmile Clients\"), excluding RedCo II but including the SPVs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RedCo II, each of the SPVs, and each of the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":12884277,"source":{"system":"sec-edgar","filing":"0001104659-26-047072","document":"tm2612392-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465926047072/tm2612392-1_4seq1.xml","form_type":"4"}},{"id":802665,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51473,"kind":"person","name":"RedCo II Master Fund, L.P.","position":3,"cik":"0001921783","reported_name":"RedCo II Master Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-23T01:51:32.000Z","date":"2026-04-20","kind":"other","planned":false,"acquired":false,"shares":8977624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with an internal reorganization of RedCo II Master Fund, L.P. (\"RedCo II\"), which is one of the private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), the reported securities were distributed pro rata and in kind, for no consideration, by RedCo II to its two wholly-owned subsidiaries (collectively, the \"SPVs\"), which are also managed by Redmile. As a result, RedCo II no longer has voting or dispositive power over such securities and is no longer a beneficial owner of more than 10% of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\"), and will be dissolved. Accordingly, this Form 4 serves as an exit filing for RedCo II. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with an internal reorganization of RedCo II Master Fund, L.P. (\"RedCo II\"), which is one of the private investment vehicles managed by Redmile Group, LLC (\"Redmile\"), the reported securities were distributed pro rata and in kind, for no consideration, by RedCo II to its two wholly-owned subsidiaries (collectively, the \"SPVs\"), which are also managed by Redmile. As a result, RedCo II no longer has voting or dispositive power over such securities and is no longer a beneficial owner of more than 10% of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\"), and will be dissolved. Accordingly, this Form 4 serves as an exit filing for RedCo II. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly owned by RedCo II."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Redmile may be deemed to beneficially own the reported securities as the investment manager of RedCo II, each of the SPVs, and each of the other Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its and his respective pecuniary interest therein, if any. This report shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-047072","document":"tm2612392-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465926047072/tm2612392-1_4seq1.xml","form_type":"4"}},{"id":937108,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-16T21:03:32.000Z","date":"2026-01-15","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":400000,"derivative":{"exercise_price":1.05,"expiration_date":"2036-01-14","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001193125-26-015328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526015328/ownership.xml","form_type":"4"}},{"id":937107,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-01-16T21:03:32.000Z","date":"2026-01-15","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of restricted stock units (\"RSUs\") that vest with respect to 1/4th of the RSUs on each of January 8, 2027, January 8, 2028, January 8, 2029 and January 8, 2030, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement."}],"balance_after":487081,"source":{"system":"sec-edgar","filing":"0001193125-26-015328","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526015328/ownership.xml","form_type":"4"}},{"id":937106,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":69242,"kind":"person","name":"Adawi Kamal","position":1,"cik":"0001788393","reported_name":"Adawi Kamal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-16T21:02:16.000Z","date":"2026-01-15","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":1.05,"expiration_date":"2036-01-14","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001193125-26-015323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526015323/ownership.xml","form_type":"4"}},{"id":937105,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":69242,"kind":"person","name":"Adawi Kamal","position":1,"cik":"0001788393","reported_name":"Adawi Kamal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-16T21:02:16.000Z","date":"2026-01-15","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of restricted stock units (\"RSUs\") that vest with respect to 1/4th of the RSUs on each of January 8, 2027, January 8, 2028, January 8, 2029 and January 8, 2030, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001193125-26-015323","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526015323/ownership.xml","form_type":"4"}},{"id":937104,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26210,"kind":"person","name":"Valamehr Bahram","position":1,"cik":"0001748177","reported_name":"Valamehr Bahram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-16T21:00:59.000Z","date":"2026-01-15","kind":"grant","planned":false,"acquired":true,"shares":1300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":1300000,"derivative":{"exercise_price":1.05,"expiration_date":"2036-01-14","underlying":"Common Stock","underlying_shares":1300000},"source":{"system":"sec-edgar","filing":"0001193125-26-015294","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526015294/ownership.xml","form_type":"4"}},{"id":937103,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26210,"kind":"person","name":"Valamehr Bahram","position":1,"cik":"0001748177","reported_name":"Valamehr Bahram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-16T21:00:59.000Z","date":"2026-01-15","kind":"grant","planned":false,"acquired":true,"shares":335000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of restricted stock units (\"RSUs\") that vest with respect to 1/4th of the RSUs on each of January 8, 2027, January 8, 2028, January 8, 2029 and January 8, 2030, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement."}],"balance_after":664708,"source":{"system":"sec-edgar","filing":"0001193125-26-015294","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526015294/ownership.xml","form_type":"4"}},{"id":940908,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-01-12T21:04:22.000Z","date":"2026-01-09","kind":"sale","planned":false,"acquired":false,"shares":10589,"price":1.0648,"value":11275.1672,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 17,500 shares of Common Stock underlying RSUs granted to the Reporting Person on January 15, 2025 and 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell-to-cover\" transactions and were not made at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $1.05 to $1.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":387081,"source":{"system":"sec-edgar","filing":"0001193125-26-010356","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526010356/ownership.xml","form_type":"4"}},{"id":940907,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26210,"kind":"person","name":"Valamehr Bahram","position":1,"cik":"0001748177","reported_name":"Valamehr Bahram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-12T21:03:31.000Z","date":"2026-01-09","kind":"sale","planned":false,"acquired":false,"shares":5190,"price":1.0708,"value":5557.452,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell-to-cover\" transactions and were not made at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $1.055 to $1.085 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":329708,"source":{"system":"sec-edgar","filing":"0001193125-26-010352","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526010352/ownership.xml","form_type":"4"}},{"id":1015228,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":69242,"kind":"person","name":"Adawi Kamal","position":1,"cik":"0001788393","reported_name":"Adawi Kamal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-21T20:08:42.000Z","date":"2025-10-20","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest as to 25% of the underlying shares on October 20, 2026 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."}],"balance_after":375000,"derivative":{"exercise_price":1.54,"expiration_date":"2035-10-20","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001193125-25-245106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525245106/ownership.xml","form_type":"4"}},{"id":1015227,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":69242,"kind":"person","name":"Adawi Kamal","position":1,"cik":"0001788393","reported_name":"Adawi Kamal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-21T20:08:42.000Z","date":"2025-10-20","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of November 1, 2026, November 1, 2027, November 1, 2028, and November 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001193125-25-245106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312525245106/ownership.xml","form_type":"4"}},{"id":1074396,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-08-05T20:03:43.000Z","date":"2025-08-04","kind":"sale","planned":false,"acquired":false,"shares":9037,"price":1.0593,"value":9572.8941,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 25,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell-to-cover\" transactions and were not made at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $1.045 to $1.075 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":397670,"source":{"system":"sec-edgar","filing":"0000950170-25-102983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025102983/ownership.xml","form_type":"4"}},{"id":1074395,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26210,"kind":"person","name":"Valamehr Bahram","position":1,"cik":"0001748177","reported_name":"Valamehr Bahram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-05T20:02:34.000Z","date":"2025-08-04","kind":"sale","planned":false,"acquired":false,"shares":14466,"price":1.0643,"value":15396.1638,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 25,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell-to-cover\" transactions and were not made at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $1.04 to $1.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":334898,"source":{"system":"sec-edgar","filing":"0000950170-25-102979","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025102979/ownership.xml","form_type":"4"}},{"id":1129157,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38144,"kind":"person","name":"Lee Michael Stewart","position":1,"cik":"0001748010","reported_name":"Lee Michael Stewart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:55:53.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in full and become exercisable upon the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The stock option award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC (\"Redmile\"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds this stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile. Mr. Lee disclaims beneficial ownership of the stock option award, if any, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-25-055046","document":"tm2516695-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465925055046/tm2516695-2_4seq1.xml","form_type":"4"}},{"id":1129156,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:54:05.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in full and become exercisable upon the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The stock option award was granted to Mr. Lee, a managing director of Redmile Group, LLC (\"Redmile\"), in connection with his service as a member of the board of directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee holds this equity award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the equity award to Redmile. Mr. Lee disclaims beneficial ownership of the equity award, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the equity award except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Lee, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile and its affiliates. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-25-055045","document":"tm2516695-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465925055045/tm2516695-1_4seq1.xml","form_type":"4"}},{"id":1129155,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T20:09:33.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-079720","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025079720/ownership.xml","form_type":"4"}},{"id":1129154,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T20:09:10.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-079717","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025079717/ownership.xml","form_type":"4"}},{"id":1129153,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":79073,"kind":"person","name":"MENDLEIN JOHN","position":1,"cik":"0001238362","reported_name":"MENDLEIN JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T20:08:35.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-079716","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025079716/ownership.xml","form_type":"4"}},{"id":1129151,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38142,"kind":"person","name":"Jooss Karin","position":1,"cik":"0001754280","reported_name":"Jooss Karin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T20:08:05.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-079715","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025079715/ownership.xml","form_type":"4"}},{"id":1129152,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38107,"kind":"person","name":"EPSTEIN ROBERT S","position":1,"cik":"0001252004","reported_name":"EPSTEIN ROBERT S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T20:07:50.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-079712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025079712/ownership.xml","form_type":"4"}},{"id":1129150,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38140,"kind":"person","name":"ABERNETHY MATT","position":1,"cik":"0001724097","reported_name":"ABERNETHY MATT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T20:06:10.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in 36 equal monthly installments following May 29, 2025, such that all of the shares shall be fully vested and exercisable on May 29, 2028, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."}],"balance_after":110000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0000950170-25-079711","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025079711/ownership.xml","form_type":"4"}},{"id":1129149,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38141,"kind":"person","name":"Agarwal Shefali","position":1,"cik":"0001746830","reported_name":"Agarwal Shefali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T20:05:37.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-079710","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025079710/ownership.xml","form_type":"4"}},{"id":1129532,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":79082,"kind":"person","name":"Mozaffarian Neelufar","position":1,"cik":"0002031203","reported_name":"Mozaffarian Neelufar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T16:09:22.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-079719","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2031203/000095017025079719/ownership.xml","form_type":"4"}},{"id":1301420,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26210,"kind":"person","name":"Valamehr Bahram","position":1,"cik":"0001748177","reported_name":"Valamehr Bahram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-16T23:36:35.000Z","date":"2025-01-16","kind":"grant","planned":false,"acquired":true,"shares":1300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2025, such that all of the shares shall be fully vested and exercisable on January 1, 2028, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":1300000,"derivative":{"exercise_price":1.25,"expiration_date":"2035-01-15","underlying":"Common Stock","underlying_shares":1300000},"source":{"system":"sec-edgar","filing":"0000950170-25-006318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025006318/ownership.xml","form_type":"4"}},{"id":1301422,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-16T23:32:36.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2025, such that all of the shares shall be fully vested and exercisable on January 1, 2028, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":275000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0000950170-25-006311","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025006311/ownership.xml","form_type":"4"}},{"id":1301421,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-01-16T23:32:36.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2026, January 8, 2027, January 8, 2028 and January 8, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":406707,"source":{"system":"sec-edgar","filing":"0000950170-25-006311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025006311/ownership.xml","form_type":"4"}},{"id":1301661,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":84088,"kind":"person","name":"Bressi Jerome Charles","position":1,"cik":"0002034505","reported_name":"Bressi Jerome Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-16T18:31:40.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2025, such that all of the shares shall be fully vested and exercisable on January 1, 2028, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-01-14","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000950170-25-006310","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034505/000095017025006310/ownership.xml","form_type":"4"}},{"id":1301660,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":84088,"kind":"person","name":"Bressi Jerome Charles","position":1,"cik":"0002034505","reported_name":"Bressi Jerome Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-01-16T18:31:40.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2026, January 8, 2027, January 8, 2028 and January 8, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":335203,"source":{"system":"sec-edgar","filing":"0000950170-25-006310","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034505/000095017025006310/ownership.xml","form_type":"4"}},{"id":1304261,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-01-13T21:05:23.000Z","date":"2025-01-10","kind":"sale","planned":false,"acquired":false,"shares":5654,"price":1.55,"value":8763.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,504 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell to cover\" transactions and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $1.53 to $1.62 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":336707,"source":{"system":"sec-edgar","filing":"0000950170-25-004823","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025004823/ownership.xml","form_type":"4"}},{"id":1304260,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26210,"kind":"person","name":"Valamehr Bahram","position":1,"cik":"0001748177","reported_name":"Valamehr Bahram","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-13T21:04:38.000Z","date":"2025-01-10","kind":"sale","planned":false,"acquired":false,"shares":8705,"price":1.54,"value":13405.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,504 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021 and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell to cover\" transactions and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $1.51 to $1.62 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":349364,"source":{"system":"sec-edgar","filing":"0000950170-25-004814","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017025004814/ownership.xml","form_type":"4"}},{"id":1304471,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":84088,"kind":"person","name":"Bressi Jerome Charles","position":1,"cik":"0002034505","reported_name":"Bressi Jerome Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-01-13T16:06:16.000Z","date":"2025-01-10","kind":"sale","planned":false,"acquired":false,"shares":5980,"price":1.55,"value":9269.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 2,188 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021 and 6,660 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell to cover\" transactions and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $1.51 to $1.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":270203,"source":{"system":"sec-edgar","filing":"0000950170-25-004825","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034505/000095017025004825/ownership.xml","form_type":"4"}},{"id":1321588,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Cash-settled Swaps","published_at":"2024-12-27T02:00:15.000Z","date":"2024-12-20","kind":"other","planned":false,"acquired":false,"shares":56331,"price":1.68,"value":94636.08,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Represents the reference price associated with the cash-settled swap agreements."},{"field":"kind","element":"transactionCoding","label":"F6","text":"On the Effective Date, certain Redmile Funds closed out a portion of the swap agreements to which they were a party for cash in accordance with the terms of the swap agreements. See Footnote 8 below."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On the Effective Date, certain Redmile Funds closed out a portion of the swap agreements to which they were a party for cash in accordance with the terms of the swap agreements. See Footnote 8 below."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Certain Redmile Funds are parties to swap agreements with counterparties. Each notional share subject to each swap agreement represents the economic equivalent of one share of Common Stock. These agreements do not give the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparties thereto to acquire, hold, vote or dispose of any securities of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Redmile Funds that are parties to the swap agreements have the right to close out each swap at any time. Upon settlement of the swap agreements, either (i) the counterparty will pay to the Redmile Funds in cash an amount determined in part by reference to any increase between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement or (ii) the Redmile Funds will pay to the counterparty in cash an amount determined in part by reference to any decrease between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities reported herein are directly owned by the Redmile Funds. The reported securities may be deemed beneficially owned by Redmile as investment manager of the Redmile Funds and by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":502769,"derivative":{"exercise_price":3.02,"underlying":"Common Stock","underlying_shares":56331},"source":{"system":"sec-edgar","filing":"0001104659-24-131794","document":"tm2431906-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465924131794/tm2431906-1_4seq1.xml","form_type":"4"}},{"id":1321587,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Convertible Preferred Stock","published_at":"2024-12-27T02:00:15.000Z","date":"2024-12-20","kind":"other","planned":false,"acquired":true,"shares":116261,"price":8.4,"value":976592.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Class A Preferred Stock is convertible into Common Stock in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the \"Certificate of Designation\") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The one-for-five conversion rate is taken into account in the amount of underlying Common Stock involved in the cross trade listed under Column 7 of Table II and used to determine the price of the Class A Preferred Stock in connection with the cross trade listed under Column 8 of Table II (which is equal to five times the price per share of the Common Stock underlying the Class A Preferred Stock at the time of the cross trade, which was $1.68 per share)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 20, 2024 (the \"Effective Date\"), certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\" and such private investment vehicles, the \"Redmile Funds\") engaged in cross trades with certain other Redmile Funds with respect to their shares of the Issuer's common stock, $0.001 par value per share (the \"Common Stock\") and shares of the Issuer's non-voting Class A Convertible Preferred Stock of the Issuer (the \"Class A Preferred Stock\"). The reported transactions occurred simultaneously when the price per share of the Common Stock was $1.68, and therefore the cross trades resulted in no profit to Redmile or Jeremy Green and resulted in no change in either of their aggregate beneficial ownership."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Class A Preferred Stock is convertible into Common Stock in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the \"Certificate of Designation\") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Certificate of Designation provides that the holder may not convert any shares of Class A Preferred Stock if, after giving effect to the attempted conversion, the holder and its affiliates would beneficially own in the aggregate more than 14.99% of the number of shares of Common Stock outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Class A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Certificate of Designation provides that the holder may not convert any shares of Class A Preferred Stock if, after giving effect to the attempted conversion, the holder and its affiliates would beneficially own in the aggregate more than 14.99% of the number of shares of Common Stock outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Class A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities reported herein are directly owned by the Redmile Funds. The reported securities may be deemed beneficially owned by Redmile as investment manager of the Redmile Funds and by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2755086,"derivative":{"underlying":"Common Stock","underlying_shares":581305},"source":{"system":"sec-edgar","filing":"0001104659-24-131794","document":"tm2431906-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465924131794/tm2431906-1_4seq1.xml","form_type":"4"}},{"id":1321586,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Convertible Preferred Stock","published_at":"2024-12-27T02:00:15.000Z","date":"2024-12-20","kind":"other","planned":false,"acquired":false,"shares":116261,"price":8.4,"value":976592.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Class A Preferred Stock is convertible into Common Stock in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the \"Certificate of Designation\") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The one-for-five conversion rate is taken into account in the amount of underlying Common Stock involved in the cross trade listed under Column 7 of Table II and used to determine the price of the Class A Preferred Stock in connection with the cross trade listed under Column 8 of Table II (which is equal to five times the price per share of the Common Stock underlying the Class A Preferred Stock at the time of the cross trade, which was $1.68 per share)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 20, 2024 (the \"Effective Date\"), certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\" and such private investment vehicles, the \"Redmile Funds\") engaged in cross trades with certain other Redmile Funds with respect to their shares of the Issuer's common stock, $0.001 par value per share (the \"Common Stock\") and shares of the Issuer's non-voting Class A Convertible Preferred Stock of the Issuer (the \"Class A Preferred Stock\"). The reported transactions occurred simultaneously when the price per share of the Common Stock was $1.68, and therefore the cross trades resulted in no profit to Redmile or Jeremy Green and resulted in no change in either of their aggregate beneficial ownership."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Class A Preferred Stock is convertible into Common Stock in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the \"Certificate of Designation\") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Certificate of Designation provides that the holder may not convert any shares of Class A Preferred Stock if, after giving effect to the attempted conversion, the holder and its affiliates would beneficially own in the aggregate more than 14.99% of the number of shares of Common Stock outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Class A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Certificate of Designation provides that the holder may not convert any shares of Class A Preferred Stock if, after giving effect to the attempted conversion, the holder and its affiliates would beneficially own in the aggregate more than 14.99% of the number of shares of Common Stock outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Class A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities reported herein are directly owned by the Redmile Funds. The reported securities may be deemed beneficially owned by Redmile as investment manager of the Redmile Funds and by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2638825,"derivative":{"underlying":"Common Stock","underlying_shares":581305},"source":{"system":"sec-edgar","filing":"0001104659-24-131794","document":"tm2431906-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465924131794/tm2431906-1_4seq1.xml","form_type":"4"}},{"id":1321585,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-27T02:00:15.000Z","date":"2024-12-20","kind":"purchase","planned":false,"acquired":true,"shares":397964,"price":1.68,"value":668579.52,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On the Effective Date, certain Redmile Funds purchased and sold shares of Common Stock concurrent with the cross trades at the same price. The reported cross trade, purchase and sales transactions occurred simultaneously when the price per share of the Common Shares was $1.68, and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities reported herein are directly owned by the Redmile Funds. The reported securities may be deemed beneficially owned by Redmile as investment manager of the Redmile Funds and by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12884277,"source":{"system":"sec-edgar","filing":"0001104659-24-131794","document":"tm2431906-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465924131794/tm2431906-1_4seq1.xml","form_type":"4"}},{"id":1321584,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-27T02:00:15.000Z","date":"2024-12-20","kind":"sale","planned":false,"acquired":false,"shares":341633,"price":1.68,"value":573943.44,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On the Effective Date, certain Redmile Funds purchased and sold shares of Common Stock concurrent with the cross trades at the same price. The reported cross trade, purchase and sales transactions occurred simultaneously when the price per share of the Common Shares was $1.68, and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities reported herein are directly owned by the Redmile Funds. The reported securities may be deemed beneficially owned by Redmile as investment manager of the Redmile Funds and by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12486313,"source":{"system":"sec-edgar","filing":"0001104659-24-131794","document":"tm2431906-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465924131794/tm2431906-1_4seq1.xml","form_type":"4"}},{"id":1321583,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-27T02:00:15.000Z","date":"2024-12-20","kind":"other","planned":false,"acquired":true,"shares":1084936,"price":1.68,"value":1822692.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 20, 2024 (the \"Effective Date\"), certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\" and such private investment vehicles, the \"Redmile Funds\") engaged in cross trades with certain other Redmile Funds with respect to their shares of the Issuer's common stock, $0.001 par value per share (the \"Common Stock\") and shares of the Issuer's non-voting Class A Convertible Preferred Stock of the Issuer (the \"Class A Preferred Stock\"). The reported transactions occurred simultaneously when the price per share of the Common Stock was $1.68, and therefore the cross trades resulted in no profit to Redmile or Jeremy Green and resulted in no change in either of their aggregate beneficial ownership."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 20, 2024 (the \"Effective Date\"), certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\" and such private investment vehicles, the \"Redmile Funds\") engaged in cross trades with certain other Redmile Funds with respect to their shares of the Issuer's common stock, $0.001 par value per share (the \"Common Stock\") and shares of the Issuer's non-voting Class A Convertible Preferred Stock of the Issuer (the \"Class A Preferred Stock\"). The reported transactions occurred simultaneously when the price per share of the Common Stock was $1.68, and therefore the cross trades resulted in no profit to Redmile or Jeremy Green and resulted in no change in either of their aggregate beneficial ownership."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities reported herein are directly owned by the Redmile Funds. The reported securities may be deemed beneficially owned by Redmile as investment manager of the Redmile Funds and by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12827946,"source":{"system":"sec-edgar","filing":"0001104659-24-131794","document":"tm2431906-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465924131794/tm2431906-1_4seq1.xml","form_type":"4"}},{"id":1321582,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-27T02:00:15.000Z","date":"2024-12-20","kind":"other","planned":false,"acquired":false,"shares":1084936,"price":1.68,"value":1822692.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 20, 2024 (the \"Effective Date\"), certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\" and such private investment vehicles, the \"Redmile Funds\") engaged in cross trades with certain other Redmile Funds with respect to their shares of the Issuer's common stock, $0.001 par value per share (the \"Common Stock\") and shares of the Issuer's non-voting Class A Convertible Preferred Stock of the Issuer (the \"Class A Preferred Stock\"). The reported transactions occurred simultaneously when the price per share of the Common Stock was $1.68, and therefore the cross trades resulted in no profit to Redmile or Jeremy Green and resulted in no change in either of their aggregate beneficial ownership."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 20, 2024 (the \"Effective Date\"), certain private investment vehicles managed by Redmile Group, LLC (\"Redmile\" and such private investment vehicles, the \"Redmile Funds\") engaged in cross trades with certain other Redmile Funds with respect to their shares of the Issuer's common stock, $0.001 par value per share (the \"Common Stock\") and shares of the Issuer's non-voting Class A Convertible Preferred Stock of the Issuer (the \"Class A Preferred Stock\"). The reported transactions occurred simultaneously when the price per share of the Common Stock was $1.68, and therefore the cross trades resulted in no profit to Redmile or Jeremy Green and resulted in no change in either of their aggregate beneficial ownership."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities reported herein are directly owned by the Redmile Funds. The reported securities may be deemed beneficially owned by Redmile as investment manager of the Redmile Funds and by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":11743010,"source":{"system":"sec-edgar","filing":"0001104659-24-131794","document":"tm2431906-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465924131794/tm2431906-1_4seq1.xml","form_type":"4"}},{"id":1330729,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Convertible Preferred Stock","published_at":"2024-12-17T02:00:10.000Z","date":"2024-12-12","kind":"exercise","planned":false,"acquired":false,"shares":6022,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Class A Preferred Stock is convertible into the Issuer's common stock, $0.001 par value per share (the \"Common Stock\"), in accordance with the terms of Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the \"Certificate of Designation\") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66, which is the equivalent of a one-for-five conversion rate."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 12, 2024, a private investment vehicle managed by Redmile Group, LLC (\"Redmile\") exercised its conversion right with respect to 6,022 non-voting Class A Convertible Preferred Stock of the Issuer (the \"Class A Preferred Stock\") held directly by such private investment vehicle."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Class A Preferred Stock is convertible into the Issuer's common stock, $0.001 par value per share (the \"Common Stock\"), in accordance with the terms of Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the \"Certificate of Designation\") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66, which is the equivalent of a one-for-five conversion rate."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Certificate of Designation provides that the holder may not convert any shares of Class A Preferred Stock if, after giving effect to the attempted conversion, the holder and its affiliates would beneficially own in the aggregate more than 14.99% of the number of shares of Common Stock outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Class A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Certificate of Designation provides that the holder may not convert any shares of Class A Preferred Stock if, after giving effect to the attempted conversion, the holder and its affiliates would beneficially own in the aggregate more than 14.99% of the number of shares of Common Stock outstanding after giving effect to such attempted conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The Class A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The Class A Preferred Stock is convertible into the Issuer's common stock, $0.001 par value per share (the \"Common Stock\"), in accordance with the terms of Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the \"Certificate of Designation\") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66, which is the equivalent of a one-for-five conversion rate."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are directly owned by private investment vehicles managed by Redmile. The reported securities may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2755086,"derivative":{"underlying":"Common Stock","underlying_shares":30110},"source":{"system":"sec-edgar","filing":"0001104659-24-129070","document":"tm2431235-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465924129070/tm2431235-1_4seq1.xml","form_type":"4"}},{"id":1330728,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-17T02:00:10.000Z","date":"2024-12-12","kind":"exercise","planned":false,"acquired":true,"shares":30110,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 12, 2024, a private investment vehicle managed by Redmile Group, LLC (\"Redmile\") exercised its conversion right with respect to 6,022 non-voting Class A Convertible Preferred Stock of the Issuer (the \"Class A Preferred Stock\") held directly by such private investment vehicle."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Class A Preferred Stock is convertible into the Issuer's common stock, $0.001 par value per share (the \"Common Stock\"), in accordance with the terms of Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the \"Certificate of Designation\") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66, which is the equivalent of a one-for-five conversion rate."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 12, 2024, a private investment vehicle managed by Redmile Group, LLC (\"Redmile\") exercised its conversion right with respect to 6,022 non-voting Class A Convertible Preferred Stock of the Issuer (the \"Class A Preferred Stock\") held directly by such private investment vehicle."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Class A Preferred Stock is convertible into the Issuer's common stock, $0.001 par value per share (the \"Common Stock\"), in accordance with the terms of Issuer's Amended and Restated Certificate of Incorporation and the Issuer's Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (as amended and restated, the \"Certificate of Designation\") at any time and from time to time at the holder's election based on a conversion ratio equal to the Class A Preferred Stock's stated value of $13.30 divided by its conversion price of $2.66, which is the equivalent of a one-for-five conversion rate."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Since the last Form 4 filing by Redmile and Mr. Green, Redmile has ceased serving as the investment adviser to a sub-advised account that held 382,552 shares of the Issuer's Common Shares (such shares, the \"Account Shares\") and therefore no longer has voting or dispositive power with respect to such shares. Accordingly, the amount of shares beneficially owned by Redmile and Mr. Green as disclosed herein does not include the Account Shares and each of Redmile and Mr. Green disclaims beneficial ownership of the Account Shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities reported herein are directly owned by private investment vehicles managed by Redmile. The reported securities may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12827946,"source":{"system":"sec-edgar","filing":"0001104659-24-129070","document":"tm2431235-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465924129070/tm2431235-1_4seq1.xml","form_type":"4"}},{"id":1438723,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-07T20:01:01.000Z","date":"2024-08-06","kind":"sale","planned":true,"acquired":false,"shares":633,"price":4.23,"value":2677.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024."}],"balance_after":8669,"source":{"system":"sec-edgar","filing":"0000950170-24-092718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024092718/ownership.xml","form_type":"4"}},{"id":1445227,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26210,"kind":"person","name":"Valamehr Bahram","position":1,"cik":"0001748177","reported_name":"Valamehr Bahram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2024-07-31T22:05:23.000Z","date":"2024-07-29","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were granted pursuant to a restricted stock unit award.  100,000 of the units are subject to time-based vesting and 100,000 of the units are subject to performance-based vesting.  25,000 time-based units will vest on August 1, 2025 and 75,000 time-based units will vest on August 1, 2026, so long as the reporting person continues to serve as an employee of the issuer through each vesting date. Subject to the achievement of specified late-stage clinical and regulatory milestones of the issuer on or before July 29, 2028, half of the performance-based units will vest one year after the achievement of two of three of the milestones, and the remaining 50,000 of the performance-based units will vest on the date one year after the achievement of all three of the milestones, in each case subject to the grantee's continued employment with the issuer through each such vesting date."}],"balance_after":358069,"source":{"system":"sec-edgar","filing":"0000950170-24-088775","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024088775/ownership.xml","form_type":"4"}},{"id":1445226,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2024-07-31T22:00:56.000Z","date":"2024-07-29","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were granted pursuant to a restricted stock unit award.  100,000 of the units are subject to time-based vesting and 100,000 of the units are subject to performance-based vesting.  25,000 time-based units will vest on August 1, 2025 and 75,000 time-based units will vest on August 1, 2026, so long as the reporting person continues to serve as an employee of the issuer through each vesting date. Subject to the achievement of specified late-stage clinical and regulatory milestones of the issuer on or before July 29, 2028, half of the performance-based units will vest one year after the achievement of two of three of the milestones, and the remaining 50,000 of the performance-based units will vest on the date one year after the achievement of all three of the milestones, in each case subject to the grantee's continued employment with the issuer through each such vesting date."}],"balance_after":342361,"source":{"system":"sec-edgar","filing":"0000950170-24-088769","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024088769/ownership.xml","form_type":"4"}},{"id":1445478,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":79082,"kind":"person","name":"Mozaffarian Neelufar","position":1,"cik":"0002031203","reported_name":"Mozaffarian Neelufar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-31T18:01:44.000Z","date":"2024-07-29","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in 36 equal monthly installments after the grant date, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":5.41,"expiration_date":"2034-07-29","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-24-088770","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2031203/000095017024088770/ownership.xml","form_type":"4"}},{"id":1483337,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38144,"kind":"person","name":"Lee Michael Stewart","position":1,"cik":"0001748010","reported_name":"Lee Michael Stewart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T22:20:25.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in full and become exercisable upon the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The stock option award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC (\"Redmile\"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds this stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile. Mr. Lee disclaims beneficial ownership of the stock option award, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended."}],"balance_after":40000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-24-070507","document":"tm2416874-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465924070507/tm2416874-2_4seq1.xml","form_type":"4"}},{"id":1483335,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T22:19:21.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in full and become exercisable upon the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The stock option award was granted to Mr. Lee, a managing director of Redmile Group, LLC (\"Redmile\"), in connection with his service as a member of the board of directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee holds this equity award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the equity award to Redmile. Mr. Lee disclaims beneficial ownership of the equity award, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the equity award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Lee, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile and its affiliates. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended."}],"balance_after":40000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-24-070506","document":"tm2416874-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465924070506/tm2416874-1_4seq1.xml","form_type":"4"}},{"id":1483336,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":32781,"kind":"person","name":"RASTETTER WILLIAM H","position":1,"cik":"0001205903","reported_name":"RASTETTER WILLIAM H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T20:35:12.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-071970","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024071970/ownership.xml","form_type":"4"}},{"id":1483334,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38142,"kind":"person","name":"Jooss Karin","position":1,"cik":"0001754280","reported_name":"Jooss Karin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T20:30:20.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-071959","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024071959/ownership.xml","form_type":"4"}},{"id":1483333,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":37659,"kind":"person","name":"Coughlin Timothy","position":1,"cik":"0001376043","reported_name":"COUGHLIN TIMOTHY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T20:29:36.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-071950","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024071950/ownership.xml","form_type":"4"}},{"id":1483332,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38141,"kind":"person","name":"Agarwal Shefali","position":1,"cik":"0001746830","reported_name":"Agarwal Shefali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T20:28:48.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-071948","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024071948/ownership.xml","form_type":"4"}},{"id":1483331,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38143,"kind":"person","name":"Xu Yuan","position":1,"cik":"0001858214","reported_name":"Xu Yuan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T20:28:42.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-071947","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024071947/ownership.xml","form_type":"4"}},{"id":1483330,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":38107,"kind":"person","name":"EPSTEIN ROBERT S","position":1,"cik":"0001252004","reported_name":"EPSTEIN ROBERT S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T20:28:20.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-071945","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024071945/ownership.xml","form_type":"4"}},{"id":1483328,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":79073,"kind":"person","name":"MENDLEIN JOHN","position":1,"cik":"0001238362","reported_name":"MENDLEIN JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T20:27:00.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-071941","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024071941/ownership.xml","form_type":"4"}},{"id":1561811,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to Purchase Common Stock","published_at":"2024-03-26T01:30:19.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":3636364,"price":5.499,"value":19996365.636,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 21, 2024, concurrently with the underwritten public offering of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), a private investment vehicle managed by Redmile Group, LLC (\"Redmile\") acquired pre-funded warrants (the \"Pre-Funded Warrants\") to purchase shares of Common Stock (the \"Pre-Funded Warrant Shares\") for a purchase price per Pre-Funded Warrant equal to $5.50, less $0.001, in a private placement by the Issuer to certain investors pursuant to the terms of a securities purchase agreement, dated as of March 19, 2024 (the \"Purchase Agreement\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable by the holder at any time on or after the closing date of the Purchase Agreement until fully exercised at an exercise price of $0.001 per Pre-Funded Warrant Share, subject to a 9.99% beneficial ownership blocker and a limitation on the right of the Issuer to issue the Pre-Funded Warrant Shares if and the extent that such exercise would violate the rules or regulations of Nasdaq Stock Market LLC. The Pre-Funded Warrants have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities reported herein are directly owned by the certain private investment vehicles managed by Redmile, none of which individually is a 10% owner. The reported securities may be deemed beneficially owned by Redmile as investment manager of the private investment vehicles and by Jeremy Green as the managing principal of Redmile. Each of Redmile and Mr. Green (the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that the Reporting Persons are a beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3893674,"derivative":{"exercise_price":0.001,"exercise_date":"2024-03-21","underlying":"Common Stock","underlying_shares":3636364},"source":{"system":"sec-edgar","filing":"0001104659-24-038585","document":"tm249642-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465924038585/tm249642-1_4seq1.xml","form_type":"4"}},{"id":1595466,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-05T21:24:31.000Z","date":"2024-03-04","kind":"sale","planned":true,"acquired":false,"shares":2447,"price":7.77,"value":19013.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023."}],"balance_after":101479,"source":{"system":"sec-edgar","filing":"0000950170-24-025992","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024025992/ownership.xml","form_type":"4"}},{"id":1661470,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":94666,"kind":"person","name":"Wolchko J Scott","position":1,"cik":"0001586893","reported_name":"Wolchko J Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-02T21:10:45.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":500000,"derivative":{"exercise_price":6.76,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000950170-24-010491","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024010491/ownership.xml","form_type":"4"}},{"id":1661469,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-02T21:10:17.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":425000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":425000,"derivative":{"exercise_price":6.76,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0000950170-24-010490","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024010490/ownership.xml","form_type":"4"}},{"id":1661468,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-02T21:09:58.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":425000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":425000,"derivative":{"exercise_price":6.76,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0000950170-24-010485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024010485/ownership.xml","form_type":"4"}},{"id":1661467,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26210,"kind":"person","name":"Valamehr Bahram","position":1,"cik":"0001748177","reported_name":"Valamehr Bahram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-02T21:09:29.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":450000,"derivative":{"exercise_price":6.76,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000950170-24-010484","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024010484/ownership.xml","form_type":"4"}},{"id":1666434,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-30T21:01:19.000Z","date":"2024-01-29","kind":"sale","planned":true,"acquired":false,"shares":1849,"price":5,"value":9245.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023."}],"balance_after":103926,"source":{"system":"sec-edgar","filing":"0000950170-24-008803","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024008803/ownership.xml","form_type":"4"}},{"id":1681526,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2024-01-10T21:30:36.000Z","date":"2024-01-09","kind":"sale","planned":false,"acquired":false,"shares":10874,"price":4.37,"value":47519.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the Reporting Person on January 8, 2020, 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell to cover\" transactions and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $4.02 to $4.50 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":142361,"source":{"system":"sec-edgar","filing":"0000950170-24-003652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024003652/ownership.xml","form_type":"4"}},{"id":1681525,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26210,"kind":"person","name":"Valamehr Bahram","position":1,"cik":"0001748177","reported_name":"Valamehr Bahram","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2024-01-10T21:30:15.000Z","date":"2024-01-09","kind":"sale","planned":false,"acquired":false,"shares":11271,"price":4.38,"value":49366.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the Reporting Person on January 8, 2020, 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell to cover\" transactions and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $4.01 to $4.50 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":158069,"source":{"system":"sec-edgar","filing":"0000950170-24-003650","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024003650/ownership.xml","form_type":"4"}},{"id":1681524,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":94666,"kind":"person","name":"Wolchko J Scott","position":1,"cik":"0001586893","reported_name":"Wolchko J Scott","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-10T21:29:56.000Z","date":"2024-01-09","kind":"sale","planned":false,"acquired":false,"shares":14391,"price":4.37,"value":62888.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 16,500 shares of Common Stock underlying RSUs granted to the Reporting Person on January 8, 2020 and 10,808 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through \"sell to cover\" transactions and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $4.02 to $4.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":371248,"source":{"system":"sec-edgar","filing":"0000950170-24-003648","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024003648/ownership.xml","form_type":"4"}},{"id":1681523,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-10T21:29:38.000Z","date":"2024-01-09","kind":"sale","planned":false,"acquired":false,"shares":7028,"price":4.37,"value":30712.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021 and 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold ranging from $4.02 to $4.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":105775,"source":{"system":"sec-edgar","filing":"0000950170-24-003647","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024003647/ownership.xml","form_type":"4"}},{"id":1692003,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-03T21:03:17.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":5182,"price":3.66,"value":18966.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023."}],"balance_after":112803,"source":{"system":"sec-edgar","filing":"0000950170-24-000874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017024000874/ownership.xml","form_type":"4"}},{"id":1698503,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T02:30:16.000Z","date":"2023-12-26","kind":"purchase","planned":false,"acquired":true,"shares":44630,"price":3.72,"value":166023.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are directly owned by the Redmile Funds, none of which individually is a 10% owner. The reported securities may be deemed beneficially owned by Redmile as investment manager of the Redmile Funds and by Jeremy Green as the managing principal of Redmile. Each of Redmile and Mr. Green (the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that the Reporting Persons are a beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":13180388,"source":{"system":"sec-edgar","filing":"0001104659-23-130203","document":"tm2333829-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465923130203/tm2333829-2_4seq1.xml","form_type":"4"}},{"id":1698502,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T02:30:16.000Z","date":"2023-12-26","kind":"other","planned":false,"acquired":true,"shares":1655370,"price":3.72,"value":6157976.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 26, 2023, certain private investment vehicles managed by Redmile (the \"Redmile Funds\") engaged in cross trades with respect to their Common Stock. The reported transactions occurred simultaneously at the market close, at which time the price per share of the Common Stock was $3.72, and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green and resulted in no change in either of their aggregate beneficial ownership."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are directly owned by the Redmile Funds, none of which individually is a 10% owner. The reported securities may be deemed beneficially owned by Redmile as investment manager of the Redmile Funds and by Jeremy Green as the managing principal of Redmile. Each of Redmile and Mr. Green (the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that the Reporting Persons are a beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":13135758,"source":{"system":"sec-edgar","filing":"0001104659-23-130203","document":"tm2333829-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465923130203/tm2333829-2_4seq1.xml","form_type":"4"}},{"id":1698501,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T02:30:16.000Z","date":"2023-12-26","kind":"other","planned":false,"acquired":false,"shares":1655370,"price":3.72,"value":6157976.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 26, 2023, certain private investment vehicles managed by Redmile (the \"Redmile Funds\") engaged in cross trades with respect to their Common Stock. The reported transactions occurred simultaneously at the market close, at which time the price per share of the Common Stock was $3.72, and therefore the reported transactions resulted in no profit to Redmile or Jeremy Green and resulted in no change in either of their aggregate beneficial ownership."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are directly owned by the Redmile Funds, none of which individually is a 10% owner. The reported securities may be deemed beneficially owned by Redmile as investment manager of the Redmile Funds and by Jeremy Green as the managing principal of Redmile. Each of Redmile and Mr. Green (the \"Reporting Persons\") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that the Reporting Persons are a beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":13135758,"source":{"system":"sec-edgar","filing":"0001104659-23-130203","document":"tm2333829-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000110465923130203/tm2333829-2_4seq1.xml","form_type":"4"}},{"id":1704711,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":28787,"kind":"person","name":"Dulac Edward J III","position":1,"cik":"0001821530","reported_name":"Dulac Edward J III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-19T21:01:11.000Z","date":"2023-12-18","kind":"sale","planned":true,"acquired":false,"shares":1585,"price":3.5,"value":5547.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 5, 2023."}],"balance_after":117985,"source":{"system":"sec-edgar","filing":"0001209191-23-059103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919123059103/doc4.xml","form_type":"4"}},{"id":1743776,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":26212,"kind":"person","name":"TAHL CINDY","position":1,"cik":"0001655472","reported_name":"TAHL CINDY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Secretary"}}],"security":"Common Stock","published_at":"2023-11-13T21:01:53.000Z","date":"2023-11-09","kind":"sale","planned":true,"acquired":false,"shares":24363,"price":2.4,"value":58471.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023."}],"balance_after":153235,"source":{"system":"sec-edgar","filing":"0001209191-23-054968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919123054968/doc4.xml","form_type":"4"}}],"next_cursor":"2023-11-13T21:01:53.000000Z,1743776"}